Definitive Healthcare Corp. Stock: price and insider trades · United States · SEC (Form 4)

About Definitive Healthcare Corp.

Definitive Healthcare Corp. (Nasdaq: DH) is a U.S.-listed company traded on the NASDAQ market in the United States, focused on healthcare data, analytics, and commercial intelligence. For international investors, the company is best understood as a specialized SaaS and data-infrastructure provider rather than a conventional healthcare operator. Its platform helps customers understand the healthcare ecosystem more clearly by organizing proprietary and public data into actionable intelligence on providers, clinicians, claims, experts, and market opportunities. The company was founded in 2011, and Definitive Healthcare Corp. was later formed in 2021 in connection with the IPO structure. Its headquarters are in Framingham, Massachusetts, United States, with additional operations in the U.S., Sweden, and India. At the core of the business is a multi-tenant data platform that supports a suite of products used by commercial, marketing, strategy, and operations teams across healthcare-adjacent industries. The product portfolio includes market intelligence, customer targeting, patient-cohort analytics, performance monitoring, expert identification, and workflow tools. Key product families include Atlas, Latitude, Passport, and Monocl, which serve different use cases such as healthcare market mapping, cohort discovery, life-science commercial planning, promotional analytics, and medical/expert network identification. The customer base is broad and includes life sciences companies, medical device firms, healthcare providers, software and IT vendors, consulting groups, financial services firms, staffing companies, and other businesses that sell into or operate around healthcare. From a competitive standpoint, Definitive Healthcare occupies a niche with relatively high switching costs and differentiation driven by data breadth, freshness, workflow integration, and analytical depth. The company’s positioning depends on the quality of its proprietary datasets, its use of AI and natural language processing, and the human research layer used to validate and enrich records. In practical terms, its moat is less about scale in the consumer sense and more about being a trusted source of healthcare commercial intelligence for enterprise customers. Although the company has a global footprint, the United States remains its principal market and the main engine of revenue generation. Recent developments are important for investors. On February 26, 2026, Definitive Healthcare reported full-year 2025 results, with annual revenue of $241.5 million and improved adjusted profitability versus prior periods, while still recording material goodwill impairment charges. The company also continued to refresh and extend its product stack, including a broader push into adjacent analytics use cases. In addition, the company’s investor-relations site and SEC filings show ongoing insider transaction activity through Form 4 disclosures in 2025 and 2026, underlining that the stock remains actively followed by market participants on the NASDAQ.